SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance

Core Viewpoint - SciSparc Ltd. has received a notification from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement for continued listing, reporting stockholders' equity of approximately $(81,000) as of June 30, 2025, against a required minimum of $2,500,000 [1][2] Group 1: Compliance and Financial Status - The company has 45 calendar days to submit a plan to regain compliance, with a deadline of February 26, 2026, and may receive an extension of up to 180 days if the plan is accepted [2] - The company expects to demonstrate compliance with Nasdaq's stockholders' equity requirement as of December 31, 2025, following proceeds from a conversion of $4.2 million in principal and accrued interest from debentures and a registered direct offering in November 2025 [3] Group 2: Company Overview - SciSparc Ltd. focuses on clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., with a portfolio centered on cannabinoid pharmaceuticals [4] - Current drug development programs include SCI-110 for Tourette syndrome and Alzheimer's disease, and SCI-210 for autism spectrum disorder and status epilepticus [4]